/ /


Latest research brings awareness to new AMD discoveriesResearch on treatments and/or causes of age-related macular degeneration (AMD) covers a wide range of approaches and paradigms. The latest research published in the past three months are perfect examples for understanding and treating AMD.
Five secrets to success with co-management
Five secrets to success with co-managementFive ophthalmologists share how to make the most of a co-managed relationship for smoother patient handoff, improved preoperative experiences, and better postoperative outcomes.
Dr. Mali's top 5 predictions in ophthalmology for 2018
Dr. Mali's top 5 predictions in ophthalmology for 2018Josh Mali, MD, shares his predictions for the 2018 ophthalmic year.
Lessons learned from Shake Shack and Danny Meyer
Lessons learned from Shake Shack and Danny MeyerOT blogger Donna Suter shares the essential keys to success from master entrepreneur Danny Meyer, founder of Shake Shack. Implementing his tips will make your practice flourish!
These novel strategies may change DME treatment paradigmThere is subset of patients with resistant or persistent DME that forms the impetus for new treatment strategies, including next-generation anti-VEGF-A and new classes of drugs. Pravin U. Dugel, MD, outlines a list of potential treatment candidates that may lead that paradigm shift.
Novel accommodating IOL achieves unique level of accommodative change
Novel accommodating IOL achieves unique level of accommodative changeA prototype of a novel dual-mode, accommodating-disaccommodating intraocular lens with zonular capture haptics has been fabricated successfully. The lens has shown in bench studies to exhibit axial shift and shape change that results in up to about 26 D of accommodative change,
Toric, presbyopia-correcting IOLs good options for glaucoma patientsSteven Vold, MD, reports that toric IOLs provide an accurate, safe, and convenient way to correct astigmatism and uncorrected distance vision for glaucoma patients, while patients wanting presbyopic correction have IOL options to fit a range of visual needs.
Most-talked-about journal articles bring ‘awareness’ to AMDTwo of the top 10 “most-talked-about” articles in JAMA Ophthalmology are about age-related macular degeneration (AMD). One of the current top 5 “most-read” articles in the American Journal of Ophthalmology is also about AMD. Here are a brief synopsis of those three papers.
AAO practice patterns offers ‘awareness’ to proper AMD treatmentThe American Academy of Ophthalmology’s Preferred Practice Pattern on Age-Related Macular Degeneration “are based on the best available scientific data as interpreted by panels of knowledgeable health professionals.” These patterns offer solid clinical guidelines for treating and counseling AMD patients.
FDA approval of retinal dystrophy drug launches era of ocular gene therapyVoretigene neparvovec-rzyl (Luxturna, Spark Therapeutics) was approved in December 2017 for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy. Clinical trial results and patient selection issues for this gene therapy are discussed.